KRAUSZ, Máté, Noriko MITSUIKI, Valeria FALCONE, Johanna KOMP, Sara POSADAS-CANTERA, Lorenz HANNS-MARTIN, Jiří LITZMAN, Daniel WOLFF, Maria KANARIOU, Anita HEINKELE, Carsten SPECKMANN, Georg HÄCKER, Hartmut HENGEL, Laura GÁMEZ-DÍAZ and Bodo GRIMBACHER. Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency? Frontiers in immunology. LAUSANNE: FRONTIERS MEDIA SA, 2022, vol. 13, November 2022, p. 1-10. ISSN 1664-3224. Available from: https://dx.doi.org/10.3389/fimmu.2022.1011646.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
Authors KRAUSZ, Máté, Noriko MITSUIKI, Valeria FALCONE, Johanna KOMP, Sara POSADAS-CANTERA, Lorenz HANNS-MARTIN, Jiří LITZMAN (203 Czech Republic, belonging to the institution), Daniel WOLFF, Maria KANARIOU, Anita HEINKELE, Carsten SPECKMANN, Georg HÄCKER, Hartmut HENGEL, Laura GÁMEZ-DÍAZ and Bodo GRIMBACHER (guarantor).
Edition Frontiers in immunology, LAUSANNE, FRONTIERS MEDIA SA, 2022, 1664-3224.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30102 Immunology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.300
RIV identification code RIV/00216224:14110/22:00127289
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fimmu.2022.1011646
UT WoS 000886594800001
Keywords in English cytotoxic T-lymphocyte antigen 4 (CTLA-4); immunodeficencies; immune dysregulation; inborn errors of immunity (IEI); disease modifiers
Tags 14110114, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 16/1/2023 11:57.
Abstract
Purpose: Heterozygous mutations in CTLA4 lead to an inborn error of immunity characterized by immune dysregulation and immunodeficiency, known as CTLA-4 insufficiency. Cohort studies on CTLA4 mutation carriers showed a reduced penetrance (around 70%) and variable disease expressivity, suggesting the presence of modifying factors. It is well studied that infections can trigger autoimmunity in humans, especially in combination with a genetic predisposition. Methods: To investigate whether specific infections or the presence of specific persisting pathogens are associated with disease onset or severity in CTLA-4 insufficiency, we have examined the humoral immune response in 13 CTLA4 mutation carriers, seven without clinical manifestation and six with autoimmune manifestations, but without immunoglobulin replacement therapy against cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1/2 (HSV 1/2), parvovirus B19 and Toxoplasma gondii. Additionally, we have measured FcγRIII/CD16A activation by EBV-specific IgG antibodies to examine the functional capabilities of immunoglobulins produced by CTLA4 mutation carriers. Results: The seroprevalence between affected and unaffected CTLA4 mutation carriers did not differ significantly for the examined pathogens. Additionally, we show here that CTLA4 mutation carriers produce EBV-specific IgG, which are unimpaired in activating FcγRIII/CD16A. Conclusions: Our results show that the investigated pathogens are very unlikely to trigger the disease onset in CTLA-4-insufficient individuals, and their prevalence is not correlated with disease severity or expressivity.
PrintDisplayed: 19/8/2024 22:15